Business UpdateJun 17, 2026, 08:31 AM
Gelteq to Start Human Clinical Trial Next Quarter; Secures $3.5M Debt
AI Summary
Gelteq Limited provided a corporate update highlighting significant clinical and commercial milestones. The company completed planning for its first human clinical trial, anticipated to begin next quarter, and commenced a veterinary clinical trial for an antiparasitic drug candidate, targeting a 2026 FDA application. Gelteq also initiated a preclinical diabetes study, secured strategic debt financing of up to US$3.5 million, and manufactured a commercial product for a new East Asian customer. Additionally, the company established a Center of Excellence in China to accelerate product development and expand its global footprint.
Key Highlights
- Human clinical trial planning completed, expected to commence next quarter (beginning July 1, 2026).
- Strategic debt financing of up to US$3.5 million secured with an institutional investor.
- Veterinary clinical trial commenced for an antiparasitic drug candidate, targeting FDA application later in 2026.
- Preclinical diabetes study commenced, expanding the pharmaceutical pipeline.
- Commercial product manufactured for a new customer in East Asia, with delivery expected in June 2026.
- Center of Excellence established in Guangdong Province, China.
- Shareholder meeting on June 18, 2026, to vote on remaining US$2.5M debt tranche.
Price Impact
More from GELS